Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A  systematic review and meta-analysis of randomized controlled trials

CONCLUSIONS: There is high certainty that CGRP mAbs are more effective than placebo, but the effect size is small. When feasible, CGRP mAbs may be prescribed as first-line preventives; topiramate or divalproex could be as effective but are less well tolerated. The findings of this study support the recently published 2024 position of the American Headache Society on the use of CGRP mAbs as the first-line treatment.PMID:38634515 | DOI:10.1111/head.14693

Source: Headache - April 18, 2024 Category: Neurology Authors: Jennifer Robblee Sameh M Hakim John M Reynolds Teshamae S Monteith Niushen Zhang Meredith Barad Source Type: research